International Biotechnology (LON:IBT) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

International Biotechnology (LON:IBT) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 684.42 ($8.38) and traded as high as GBX 703.25 ($8.61). International Biotechnology shares last traded at GBX 702 ($8.59), with a volume of 145,383 shares.

International Biotechnology Stock Performance

The company has a fifty day moving average of GBX 695.23 and a two-hundred day moving average of GBX 684.42. The firm has a market capitalization of £260.95 million, a price-to-earnings ratio of 1,470.90 and a beta of 0.21. The company has a debt-to-equity ratio of 9.66, a quick ratio of 0.32 and a current ratio of 0.46.

International Biotechnology Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, January 24th. Shareholders of record on Thursday, December 19th will be given a dividend of GBX 15.56 ($0.19) per share. This is a boost from International Biotechnology’s previous dividend of $14.50. The ex-dividend date of this dividend is Thursday, December 19th. This represents a yield of 2.21%. International Biotechnology’s dividend payout ratio (DPR) is presently 6,041.67%.

Insider Activity

In other International Biotechnology news, insider Katherine Cornish-Bowden purchased 1,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The stock was bought at an average cost of GBX 713 ($8.73) per share, for a total transaction of £10,695 ($13,090.58). 4.18% of the stock is currently owned by company insiders.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.